The present invention relates to crystalline forms of (1r,4r)-6-fluoro-N,N-dimethyl-4-phenyl-4,9-dihydro-3l-l-spiro[cyclohexane-1,1 -pyrano[3,4,b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for the enrichment of them.Linvention concerne des formes cristallines de (1r,4r)-6-fluoro-N,N-diméthyl-4-phényl-4,9-dihydro-3H-spiro[cyclohexane-1,1-pyrano[3,4,b]indol]-4-amine, des compositions pharmaceutiques et des médicaments contenant ces modifications, lutilisation de ces modifications, ainsi quun procédé denrichissement associé.
